Nordic Microbiota Meeting 2026
Keywords:The purpose of this academic training is to explore clinical and translational research in intestinal microbiome science, facilitate networking between early-career and experienced researchers, and promote collaboration in microbiome research across the five Nordic countries.
Participation is open to clinicians and researchers working on microbiome therapies in the Nordic countries as well as the Baltic countries. The number of participants is limited to 100. The steering committee will ensure a balanced representation across countries, specialties, and levels of seniority.
Haartmaninkatu 4, Helsinki, Finland
Date: Tuesday, 25 August 2026, at noon – Wednesday, 26 August 2026, at 4:00 p.m.
Send abstracts to:
perttu.arkkila@hus.fi (cc: reetta.satokari@helsinki.fi)
Write in the subject field: “NorMic 2026 Abstract”
Participants are entitled to a discount on room reservations at Scandic hotels. The Scandic hotel closest to Meilahti Bridge Hospital is called Scandic Meilahti. Room reservations can be made through the following link: BOOK ACCOMMODATION. By using link above, you will automatically receive the discounted room rate.
You can choose the room type you prefer and receive an additional discount if you pay for the room at the time of booking. The cancellation policy for an individual reservation depends on the room type selected by the guest. To confirm the reservation, the guest must provide valid credit card details to the hotel. Rooms can be booked depending on the hotel’s availability, up to 10 days before arrival.
Tuesday 25th August 2026, Lecture hall Kruunuhaka
- -
-
Opening of the meeting, Professor Perttu Arkkila and Adjunct professor Reetta Satokari
- -
-
Highlights in microbiota studies in Nordic and Baltic countries: each country represents few published studies 10min+5 min discussion
Christian Lodberg Hvas, Johannes Hov, Juozas Kupcinskas, Perttu Arkkila - -
-
Lunch beside Siltasairaala Ravioli restaurant
- -
-
Meetings at seminar rooms
Seminar Room 1: Microbiota Reetta Satokari
Lean-donor gut microbiota engraftment and host responses in adults with severe obesity: a randomized controlled study, Ching Jian, University of Helsinki
Emerging Microbiome-Derived Metabolites: What do we still not know about Gut Microbial Metabolism and its links to host physiology?, Santosh Lamichhane, University of Turku
Dialisteraceae as a Candidate Biomarker of Clinical Outcomes in Newly Diagnosed Multiple Myeloma: The REMNANT Study, Pegah Abdollahi, Oslo University Hospital
Seminar Room 2: FMT clinical 1: Metabolic-related diseases Chairman TBA
Faecal microbiota transplantation for patients with type 1 diabetes complicated by gastroenteropathy (Fadigas2): A study protocol for a multicentre randomised placebo-controlled trial, Ditte Smed Kornum, Aarhus University Hospital and Aarhus University
Clinical improvement after faecal microbiota transplantation in type 1 diabetes with gastroenteropathy is independent of global microbiome shifts, Katrine Lundby Høyer, Aarhus University Hospital
Nordic Multicenter FMT Trial in Male Anorexia Nervosa, A Call for Collaboration, Kenneth Klingenberg Barfod, University of Copenhagen
Seminar Room 4: FMT clinical 2: Challenge-to-treat diseases Juozas Kupcinskas
FMT in Graft versus Host disease, Olga Pankratova, Helsinki University Hospital
Safety and pilot efficacy of faecal microbiota transplantation against chronic diarrhoea in patients with systemic sclerosis, Nanna S Rolighed, Aarhus University Hospital and Aarhus University
Fecal microbiota transplantation on axial spondyloarthritis: Clinical results and microbiome changes, Anna Hartikainen, University of Helsinki
- -
-
Coffee break
- -
-
Key note lecture: Gut microbiota and cancer
Margherita Ferrari, MD, Gastroenterology resident
Department of Translational Medicine and Surgery, Università Cattolica del Sacro Cuore, Rome, Italy - -
-
Dinner at downtown Helsinki
Wednesday 26 th August 2026 Lecture hall Kruunuhaka
- -
-
Microbes as medicines
Willem M. de Vos, PhD, Emeritus Distinguished Professor, Wageningen University, Nl and University of Helsinki, FI
- -
-
Clostridioides difficile infection; pretreatment, optimal route and time for FMT
Emil Juul, MD, PhD, Clinical Effectiveness Research Group, Oslo University Hospital, Rikshospitalet, Associate professor, University of Oslo, Institute of Health and Society
- -
-
Gut microbiome’s role in brain health and neurological diseases
Filip Scheperjans, Adjunct professor, Helsinki University and Helsinki University Hospital
- -
-
Coffee break
- -
-
Microbiome testing in clinical practice
Juozas Kupcinskas, Prof., MD, PhD, Vice Rector for Research, Head of Gastroenterology Department, Lithuanian University of Health Sciences, Kaunas, Lithuania
- -
-
Beyond the “easy win” indication for FMT
Professor Christian Lodberg Hvas, Århus University
- -
-
Gut microbiota for precision nutrition – where do we stand?
Anne Salonen, Adjunct professor, MD, PhD, University of Helsinki
- -
-
Lunch at beside Siltasairaala Ravioli restaurant
- -
-
Meetings at seminar rooms (15+5 min presentations)
Seminar Room 1: Variations of microbiome therapies, Chairman TBA
Fecal virome transplantation in patients with Clostridioides difficile infection -results from a randomized controlled pilot trial, Frederik Cold, Odense University Hospital and Copenhagen University Hospital Hvidovre
Exploring the microbial restoring potential of an anaerobic bacterial blend in an antibiotic disrupted gut ecosystem in vitro model M-SHIME, Berta Bosch, University of Helsinki
Gut microbiome and fecal metabolomics in children with cancer Viktoria K. Malnes. Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway
Seminar Room 2: Capsulated FMT Perttu Arkkila
KISS: Keep it simple and sweet: a new and more effective method to produce FMT in capsules, Arne Kötz, Clinical microbiology, Halmstad, Sweden
Development of an Automated Manufacturing Platform for Standardized Fecal Microbiota Transplantation Capsules, Hengameh Chloe Lauridsen, Copenhagen University Hospital – Amager and Hvidovre
Seminar Room 4 : GUT-Brain and other interactions Chairman TBA
Title: Subjective–Objective Discordance in Parkinson's Disease Constipation: Insights From Constipation Phenotypes, Noora Vetkas, Helsinki University Hospital
Antibiotic therapy, not disease severity, shapes the intestinal and oral microbiomes in acutely decompensated cirrhosis. Søren Damsholt, Aarhus University Hospital
Effects of fecal microbiota transplantation on activities of cytochrome P450 enzymes – a clinical drug metabolism phenotyping study, Laura Aurinsalo, Helsinki University Hospital
- -
-
Functional model for multicenter clinical trials in Nordic countries: Tips for the colleagues how to organize multicenter study"
Professor Øyvind Holme II - Department of Health Management and Health Economics, Oslo
Possible collaborative clinical trials. - -
-
Short wrap-up and presenting next year's NorMic
Adjunct professor Reetta Satokari, Helsinki University
Updated: 17.07.2026